A $175 Million Move Into Sotera Health Signals Potential Opportunity Amid 21% Stock Drop

1 hour ago 1

Jonathan Ponciano, The Motley Fool

Mon, March 23, 2026 astatine 11:39 AM CDT 4 min read

On February 17, 2026, Sessa Capital disclosed a large bargain of Sotera Health (NASDAQ:SHC), adding 10,630,381 shares successful an estimated $175.80 cardinal commercialized based connected quarterly mean pricing.

According to a filing with the Securities and Exchange Commission dated February 17, 2026, Sessa Capital purchased 10,630,381 further shares of Sotera Health successful the 4th quarter. The estimated transaction worth is $175.80 million, calculated utilizing the mean closing terms for the quarter. The fund’s quarter-end presumption worth successful Sotera Health roseate by $206.47 million, a fig reflecting some trading enactment and banal terms movement.

The post-trade involvement represents adjacent to 7% of Sessa Capital’s 13F reportable assets nether management.
Top holdings aft the filing:
- NASDAQ: WBD: $1.31 cardinal (26.1% of AUM)
- NYSE: HUM: $593.94 cardinal (11.8% of AUM)
- NASDAQ: ILMN: $446.48 cardinal (8.9% of AUM)
- NYSE:PCG: $394.97 cardinal (7.9% of AUM)
- NYSE:COF: $377.65 millino (7.5% of AUM)
As of Monday, SHC shares were priced astatine $13.99, up 18% implicit the past twelvemonth and somewhat outperforming the S&P 500’s astir 15% summation successful the aforesaid play arsenic a result.

Metric

Value

Price (as of Monday)	$13.99
Market capitalization	$4.0 billion
Revenue (TTM)	$1.2 billion
Net income (TTM)	$77.9 million

Sotera Health offers sterilization services (gamma, electron beam, and EO processing), laboratory testing, and advisory solutions for aesculapian device, pharmaceutical, and related industries.
The steadfast serves aesculapian instrumentality manufacturers, pharmaceutical companies, and food/agricultural merchandise providers globally.
It maintains a planetary footprint with a diversified gross basal and precocious lawsuit retention.

Sotera Health is simply a starring supplier of sterilization and laboratory investigating services, supporting captious proviso chains successful healthcare and beingness sciences. With specialized exertion and regulatory expertise, it maintains recurring gross streams and serves arsenic a cardinal spouse to aesculapian and pharmaceutical manufacturers worldwide.

Sotera has built a beardown way grounds successful healthcare services, with gross reaching astir $1.16 cardinal and adjusted EBITDA adjacent to $600 cardinal past year, marking 20 years of dependable growth. Typically, this benignant of accordant show commands a premium. However, the banal has dipped since the past 4th arsenic investors absorption connected risks from litigation, precocious leverage, and regulatory concerns.

Additionally, the marketplace has been flooded with supply. A caller secondary offering saw backstage equity backers dump 25 cardinal shares, creating a method overhang that doesn't bespeak Sotera's underlying fundamentals.

In the broader portfolio, this mirrors a trend. Substantial positions successful companies similar Warner Bros. Discovery and Illumina bespeak a willingness to clasp contention portion fundamentals stay strong, and Sotera is conscionable extracurricular the firm’s apical 5 holdings by value.

For semipermanent investors, the important question is astir durability. If Sotera tin support mid-single-digit maturation and efficaciously grip litigation risks, this caller spread betwixt its existent show and capitalist cognition won't past forever.

Read Entire Article